Adjunctive galantamine for treatment of cognitive impairments in patients with schizophrenia

Trial Profile

Adjunctive galantamine for treatment of cognitive impairments in patients with schizophrenia

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2009

At a glance

  • Drugs Galantamine (Primary)
  • Indications Cognition disorders; Schizoaffective disorder; Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Jan 2008 Results have been published.
    • 26 Jun 2007 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top